Universal Chimeric Antigen Receptors for Multiplexed and Logical Control of T Cell Responses

Bonifant, 2016, Toxicity and management in CAR T-cell therapy, Mol. Ther. Oncolytics, 3, 16011, 10.1038/mto.2016.11 Brentjens, 2011, Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias, Blood, 118, 4817, 10.1182/blood-2011-04-348540 Brentjens, 2013, CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia, Sci. Transl. Med., 5, 177ra38, 10.1126/scitranslmed.3005930 Brudno, 2016, Toxicities of chimeric antigen receptor T cells: recognition and management, Blood, 127, 3321, 10.1182/blood-2016-04-703751 Cartellieri, 2016, Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blasts, Blood Cancer J., 6, e458, 10.1038/bcj.2016.61 Carter, 2001, Improving the efficacy of antibody-based cancer therapies, Nat. Rev. Cancer, 1, 118, 10.1038/35101072 Caruso, 2015, Tuning sensitivity of CAR to EGFR density limits recognition of normal tissue while maintaining potent antitumor activity, Cancer Res., 75, 3505, 10.1158/0008-5472.CAN-15-0139 Chen, 2013, Molecular mechanisms of T cell co-stimulation and co-inhibition, Nat. Rev. Immunol., 13, 227, 10.1038/nri3405 Chmielewski, 2004, T cell activation by antibody-like immunoreceptors: increase in affinity of the single-chain fragment domain above threshold does not increase T cell activation against antigen-positive target cells but decreases selectivity, J. Immunol., 173, 7647, 10.4049/jimmunol.173.12.7647 Davila, 2014, Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia, Sci. Transl. Med., 6, 224ra25, 10.1126/scitranslmed.3008226 Di Stasi, 2011, Inducible apoptosis as a safety switch for adoptive cell therapy, N. Engl. J. Med., 365, 1673, 10.1056/NEJMoa1106152 Fry, 2018, CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy, Nat. Med., 24, 20, 10.1038/nm.4441 Fu, 2010, A simple and sensitive method for measuring tumor-specific T cell cytotoxicity, PLoS ONE, 5, e11867, 10.1371/journal.pone.0011867 Geller, 2013, Intraperitoneal delivery of human natural killer cells for treatment of ovarian cancer in a mouse xenograft model, Cytotherapy, 15, 1297, 10.1016/j.jcyt.2013.05.022 Glienke, 2015, Advantages and applications of CAR-expressing natural killer cells, Front. Pharmacol., 6, 21, 10.3389/fphar.2015.00021 Golubovskaya, 2016, Different Subsets of T Cells, Memory, Effector Functions, and CAR-T Immunotherapy, Cancers (Basel), 8, 10.3390/cancers8030036 Gould, 2005, Protective and therapeutic capacity of human single-chain Fv-Fc fusion proteins against West Nile virus, J. Virol., 79, 14606, 10.1128/JVI.79.23.14606-14613.2005 Grada, 2013, TanCAR: A Novel Bispecific Chimeric Antigen Receptor for Cancer Immunotherapy, Mol. Ther. Nucleic Acids, 2, e105, 10.1038/mtna.2013.32 Greenwald, 2005, The B7 family revisited, Annu. Rev. Immunol., 23, 515, 10.1146/annurev.immunol.23.021704.115611 Grupp, 2013, Chimeric antigen receptor-modified T cells for acute lymphoid leukemia, N. Engl. J. Med., 368, 1509, 10.1056/NEJMoa1215134 Haso, 2013, Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia, Blood, 121, 1165, 10.1182/blood-2012-06-438002 Hegde, 2013, Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma, Mol. Ther., 21, 2087, 10.1038/mt.2013.185 Hombach, 2006, Human CD4+ T cells lyse target cells via granzyme/perforin upon circumvention of MHC class II restriction by an antibody-like immunoreceptor, J. Immunol., 177, 5668, 10.4049/jimmunol.177.8.5668 Howland, 2000, The roles of CD28 and CD40 ligand in T cell activation and tolerance, J. Immunol., 164, 4465, 10.4049/jimmunol.164.9.4465 Hudecek, 2015, The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity, Cancer Immunol. Res., 3, 125, 10.1158/2326-6066.CIR-14-0127 Kane, 2001, Akt provides the CD28 costimulatory signal for up-regulation of IL-2 and IFN-gamma but not TH2 cytokines, Nat. Immunol., 2, 37, 10.1038/83144 Karin, 1997, AP-1 function and regulation, Curr. Opin. Cell Biol., 9, 240, 10.1016/S0955-0674(97)80068-3 Kawalekar, 2016, Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells, Immunity, 44, 380, 10.1016/j.immuni.2016.01.021 Kimchi-Sarfaty, 2013, Building better drugs: developing and regulating engineered therapeutic proteins, Trends Pharmacol. Sci., 34, 534, 10.1016/j.tips.2013.08.005 Klingemann, 2014, Are natural killer cells superior CAR drivers?, OncoImmunology, 3, e28147, 10.4161/onci.28147 Kloss, 2013, Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells, Nat. Biotechnol., 31, 71, 10.1038/nbt.2459 Kochenderfer, 2012, B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells, Blood, 119, 2709, 10.1182/blood-2011-10-384388 Kontermann, 2011, Strategies for extended serum half-life of protein therapeutics, Curr. Opin. Biotechnol., 22, 868, 10.1016/j.copbio.2011.06.012 Kudo, 2014, T lymphocytes expressing a CD16 signaling receptor exert antibody-dependent cancer cell killing, Cancer Res., 74, 93, 10.1158/0008-5472.CAN-13-1365 Lanitis, 2013, Chimeric antigen receptor T Cells with dissociated signaling domains exhibit focused antitumor activity with reduced potential for toxicity in vivo, Cancer Immunol. Res., 1, 43, 10.1158/2326-6066.CIR-13-0008 Lee, 2002, Intraperitoneal gene delivery mediated by a novel cationic liposome in a peritoneal disseminated ovarian cancer model, Gene Ther., 9, 859, 10.1038/sj.gt.3301704 Lengyel, 2014, Epithelial ovarian cancer experimental models, Oncogene, 33, 3619, 10.1038/onc.2013.321 Liu, 2015, Affinity-tuned ErbB2 or EGFR chimeric antigen receptor T cells exhibit an increased therapeutic index against tumors in mice, Cancer Res., 75, 3596, 10.1158/0008-5472.CAN-15-0159 Lucas, 1995, Naive CD28-deficient T cells can initiate but not sustain an in vitro antigen-specific immune response, J. Immunol., 154, 5757, 10.4049/jimmunol.154.11.5757 Luckheeram, 2012, CD4+T cells: differentiation and functions, Clin. Dev. Immunol., 2012, 925135, 10.1155/2012/925135 Ma, 2016, Versatile strategy for controlling the specificity and activity of engineered T cells, Proc. Natl. Acad. Sci. USA, 113, E450, 10.1073/pnas.1524193113 MacDonald, 2016, Alloantigen-specific regulatory T cells generated with a chimeric antigen receptor, J. Clin. Invest., 126, 1413, 10.1172/JCI82771 Maude, 2014, Chimeric antigen receptor T cells for sustained remissions in leukemia, N. Engl. J. Med., 371, 1507, 10.1056/NEJMoa1407222 Maude, 2014, Managing cytokine release syndrome associated with novel T cell-engaging therapies, Cancer J., 20, 119, 10.1097/PPO.0000000000000035 Morgan, 2010, Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2, Mol. Ther., 18, 843, 10.1038/mt.2010.24 Perna, 2016, Myeloid leukemia switch as immune escape from CD19 chimeric antigen receptor (CAR) therapy, Transl. Cancer Res., 5, S221, 10.21037/tcr.2016.08.15 Reinke, 2010, A synthetic coiled-coil interactome provides heterospecific modules for molecular engineering, J. Am. Chem. Soc., 132, 6025, 10.1021/ja907617a Rodgers, 2016, Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies, Proc. Natl. Acad. Sci. USA, 113, E459, 10.1073/pnas.1524155113 Roybal, 2016, Precision Tumor Recognition by T Cells With Combinatorial Antigen-Sensing Circuits, Cell, 164, 770, 10.1016/j.cell.2016.01.011 Ruella, 2016, Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies, J. Clin. Invest., 126, 3814, 10.1172/JCI87366 Sadelain, 2017, Therapeutic T cell engineering, Nature, 545, 423, 10.1038/nature22395 Scholler, 2012, Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells, Sci. Transl. Med., 4, 132ra53, 10.1126/scitranslmed.3003761 Scott, 2012, Antibody therapy of cancer, Nat. Rev. Cancer, 12, 278, 10.1038/nrc3236 Shaw, 2004, Characterization of intraperitoneal, orthotopic, and metastatic xenograft models of human ovarian cancer, Mol. Ther., 10, 1032, 10.1016/j.ymthe.2004.08.013 Skapenko, 2001, Antigen-independent Th2 cell differentiation by stimulation of CD28: regulation via IL-4 gene expression and mitogen-activated protein kinase activation, J. Immunol., 166, 4283, 10.4049/jimmunol.166.7.4283 Strohl, 2015, Fusion Proteins for Half-Life Extension of Biologics as a Strategy to Make Biobetters, BioDrugs, 29, 215, 10.1007/s40259-015-0133-6 Szlachcic, 2011, Longer action means better drug: tuning up protein therapeutics, Biotechnol. Adv., 29, 436, 10.1016/j.biotechadv.2011.03.005 Tamada, 2012, Redirecting gene-modified T cells toward various cancer types using tagged antibodies, Clin. Cancer Res., 18, 6436, 10.1158/1078-0432.CCR-12-1449 Thompson, 2012, SYNZIP protein interaction toolbox: in vitro and in vivo specifications of heterospecific coiled-coil interaction domains, ACS Synth. Biol., 1, 118, 10.1021/sb200015u Turtle, 2016, CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients, J. Clin. Invest., 126, 2123, 10.1172/JCI85309 Urbanska, 2012, A universal strategy for adoptive immunotherapy of cancer through use of a novel T-cell antigen receptor, Cancer Res., 72, 1844, 10.1158/0008-5472.CAN-11-3890 Vandenberghe, 1993, Ligation of the CD5 or CD28 molecules on resting human T cells induces expression of the early activation antigen CD69 by a calcium- and tyrosine kinase-dependent mechanism, Immunology, 78, 210 Vignali, 2008, How regulatory T cells work. Nat. Rev, Immunol., 8, 523 Vivier, 2008, Functions of natural killer cells, Nat. Immunol., 9, 503, 10.1038/ni1582 Wu, 2015, Remote control of therapeutic T cells through a small molecule-gated chimeric receptor, Science, 350, aab4077, 10.1126/science.aab4077 Yoon, 2017, FVIII-specific human chimeric antigen receptor T-regulatory cells suppress T- and B-cell responses to FVIII, Blood, 129, 238, 10.1182/blood-2016-07-727834 Zah, 2016, T Cells Expressing CD19/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells, Cancer Immunol. Res., 4, 498, 10.1158/2326-6066.CIR-15-0231 Zhao, 2015, Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells, Cancer Cell, 28, 415, 10.1016/j.ccell.2015.09.004 Zhu, 2007, CD137 stimulation delivers an antigen-independent growth signal for T lymphocytes with memory phenotype, Blood, 109, 4882, 10.1182/blood-2006-10-043463 Zhu, 2011, Cell surface signaling molecules in the control of immune responses: a tide model, Immunity, 34, 466, 10.1016/j.immuni.2011.04.008